Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients

被引:25
作者
Pawlak, Krystyna
Pawlak, Dariusz
Mysliwiec, Michal
机构
[1] Med Univ, Dept Nephrol & Clin Transplantat, PL-15540 Bialystok, Poland
[2] Med Univ, Dept Pharmacodynam, Bialystok, Poland
关键词
cardiovascular disease; coagulation; urokinase-type plasminogen activator system; hemodialysis;
D O I
10.1016/j.thromres.2007.01.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The disturbances of haemostasis and enhanced oxidative stress (SOX) appear to contribute to the cardiovascular disease (CVD) in hemodialysis (HD) patients. The aim of the present study was to investigate if the disorders of coagulation/fibrinolysis system are associated with the presence of CVD in these patients. Materials and methods: We compared pre-dialysis levels of uPA, suPAR, tissue factor (TF) and its inhibitor (TFPI), prothrombin fragment F1+2 (F1+2); a marker of SOX-Cu/Zn superoxide dismutase (Cu/Zn SOD) and a surrogate of inflammation-high sensitivity C-reactive protein (hs CRP) in HD patients with and without CVD. Results: The uPA/suPAR system and hs CRP values were significantly greater in patients with CVD than in those without CVD; whereas TF, TFP1, F1+2 and Cu/Zn SOD levels were comparable in both patient groups. TF was positively correlated with both uPA (p<0.001) and suPAR levels (p<0.05). Logistic regression analysis showed that elevated Levels of suPAR, TF and uPA were independently associated with the presence of CVD in HD patients. Conclusions: The association between TF and upA/suPAR system is significantly related to the presence of CVD in HD patients. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:871 / 876
页数:6
相关论文
共 35 条
  • [11] Kaikita K, 1999, J PATHOL, V188, P180, DOI 10.1002/(SICI)1096-9896(199906)188:2<180::AID-PATH338>3.0.CO
  • [12] 2-Q
  • [13] Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders
    Kanse, SM
    Benzakour, O
    Kanthou, C
    Kost, C
    Lijnen, HR
    Preissner, KT
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) : 2848 - 2854
  • [14] Changes of plasma tissue factor and tissue factor pathway inhibitor antigen levels and induction of tissue factor expression on the monocytes in coronary artery disease
    Kim, HK
    Song, KS
    Park, YS
    Yun, YS
    Shim, WH
    [J]. CARDIOLOGY, 2000, 93 (1-2) : 31 - 36
  • [15] Urokinase plasminogen activator system in humans with stable coronary artery disease
    Krasnikova, TL
    Parfyonova, YV
    Alekseeva, IA
    Arefieva, TI
    Mukhina, SA
    Dobrovolsky, AB
    Titaeva, YV
    Lyakishev, AA
    Resink, TJ
    Erne, P
    Tkachuk, VA
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1999, 26 (04) : 354 - 357
  • [16] Marcucci R, 2000, THROMB HAEMOSTASIS, V83, P826
  • [17] Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction
    May, AE
    Schmidt, R
    Kanse, SM
    Chavakis, T
    Stephens, RW
    Schömig, A
    Preissner, KT
    Neumann, FJ
    [J]. BLOOD, 2002, 100 (10) : 3611 - 3617
  • [18] UPA and uPAR in fibrinolysis, immunity and pathology
    Mondino, A
    Blasi, F
    [J]. TRENDS IN IMMUNOLOGY, 2004, 25 (08) : 450 - 455
  • [19] UROKINASE RECEPTORS IN HUMAN MONOCYTES
    NYKJAER, A
    PETERSEN, CM
    CHRISTENSEN, EI
    DAVIDSEN, O
    GLIEMANN, J
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1052 (03) : 399 - 407
  • [20] Oxidative stress effects fibrinolytic system in dialysis uraemic patients
    Pawlak, K
    Pawlak, D
    Mysliwiec, M
    [J]. THROMBOSIS RESEARCH, 2006, 117 (05) : 517 - 522